Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > Someday

<< Previous

Bullboard Posts

Next >>

Comment by wizzdumbon Aug 05, 2021 12:31pm

139 Views

Post# 33655187

RE:Someday

2021 Fiscal year end for Microbix is September and will be reported out in mid-November. Next Thursday is Q3 results that ended in June. Both will be records and will show the markets that this is a fast growing and profitable business with significant potential especially after the automation of the VTM and QAPs products is implemented. Kinlytic announcement by end of calendar year which will be transformational. Patience will be rewarded handsomely.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec